Research programme: growth differentiation factor 11 modulators - Elevian/Insilico Medicine
Alternative Names: GDF11 modulators - Elevian/Insilico Medicine; Small molecule anti-aging therapeutics - Elevian/Insilico MedicineLatest Information Update: 28 Feb 2023
At a glance
- Originator Elevian; InSilico Medicine
- Class Small molecules
- Mechanism of Action Growth differentiation factor 11 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sarcopenia
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Sarcopenia in USA (PO)
- 09 Jan 2019 Elevian and Insilico Medicine enter into a research and development partnership to develop growth differentiation factor 11 modulators
- 09 Jan 2019 Elevian acquires exclusive, worldwide rights to Harvard's patent portfolio concerning circulating factors that regulate aging, prior to January 2019